Mycoprotein Consumption and Glucose Absorption

Overview

Previous research has demonstrated that the food found in Quorn 'Mycoprotein' can lower the blood glucose response to a meal, which may be an important finding for the management of type 2 diabetes. However, it has never been investigated how this lower response occurs, and whether there is dose-dependent response with mycoprotein. The present study will include 12 healthy young adults, who will visit the laboratory for 3 test days, with each day lasting 9 hours. On each visit, separated by a washout period of at least 2 weeks, participants will ingest either a control drink with no mycoprotein, a drink containing 20g mycoprotein or a drink containing 40g mycoprotein. By intravenously infusing labelled glucose during each visit in combination with repeated blood sampling, investigators will determine if the lower blood glucose after mycoprotein ingestion is due to reduced glucose absorption from the gut or increased uptake into body tissues.

Full Title of Study: “To Determine the Effects of Mycoprotein Consumption on Glucose Absorption in Healthy Participants”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Basic Science
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: October 2019

Interventions

  • Dietary Supplement: Mycoprotein Ingestion
    • Ingestion of various doses of mycoprotein compared to placebo control

Arms, Groups and Cohorts

  • Experimental: Ingestion of 20g Mycoprotein Drink
    • Milkshake containing 20g of mycoprotein, 250ml full-fat milk, 50g glucose and 11g lactose is given to participants in one dose
  • Experimental: Ingestion of 40g Mycoprotein Drink
    • Milkshake containing 40g of mycoprotein, 250ml full-fat milk, 50g glucose and 11g lactose is given to participants in one dose
  • Placebo Comparator: Ingestion of Isocaloric Control Drink
    • Milkshake containing 250ml full-fat milk, 50g glucose, 19g dried skim milk and 9g full-fat dried milk

Clinical Trial Outcome Measures

Primary Measures

  • Glucose absorption
    • Time Frame: 6 hours following ingestion of drink
    • How glucose is absorbed following the ingestion of a mycoprotein drink compared to a placebo control measured using the infusion of stable isotopes

Secondary Measures

  • Incretin Hormones
    • Time Frame: 6 hours following ingestion of drink
    • Measurement of GLP-1 and GIP in response to mycoprotein ingestion compared to placebo control
  • Insulinaemic Response
    • Time Frame: 6 hours following ingestion of drink
    • Measurement of insulin response following ingestion of drinks
  • Production of Short-Chain Fatty Acids
    • Time Frame: 6 hours following ingestion of drink
    • Measurement of plasma acetate production in response to mycoprotein ingestion
  • Glucose Kinetics
    • Time Frame: 6 hours following ingestion of drink
    • Calculations using plasma deuterated glucose enrichment to determine rate of appearance of endogenous glucose, rate of disappearance of glucose and rate of appearance of exogenous glucose

Participating in This Clinical Trial

Inclusion Criteria

Male and female 18-35 years of age Consumption of sufficient amounts of carbohydrate in the diet Body mass index between 18.5 and 30

Exclusion Criteria

Any diagnosed metabolic impairment (e.g. type 1 or 2 Diabetes), or other form of abnormal glucose metabolism (as this will affect outcome of the study).

Any diagnosed cardiovascular disease Inusfficient consumption of carbohydrate in the diet A personal or family history of epilepsy, seizures or schizophrenia Known pre-existing liver disease/condition Allergy or intolerance to milk

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 35 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of Exeter
  • Collaborator
    • Quorn Foods
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • GrĂ¡inne Whelehan, 01392 722157, gw404@exeter.ac.uk

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.